Polymyalgia Rheumatica - Pipeline Insight, 2024

This Polymyalgia Rheumatica - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Polymyalgia Rheumatica pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Polymyalgia Rheumatica Understanding

Polymyalgia Rheumatica: Overview

Polymyalgia rheumatica (PMR) is a rheumatic disorder characterized by pain and stiffness around the neck, shoulder, and hip area. This disorder is more common in white adults over 50 years of age. It is an inflammatory condition associated with an elevation of erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP) being the common findings. PMR patients can have coexisting and/or develop giant cell arteritis (GCA).

Polymyalgia rheumatica is an immune-mediated disorder, and elevated inflammatory markers are one of the most common features. IL-6 appears to have a central role in mediating inflammation.Interferon (IFN) may be present in temporal artery biopsy in patients with GCA but not in patients with PMR, suggesting its role in the development of arteritis. An elevated IgG4 level was found in patients with PMR but less frequently so in patients with GCA. The same study discovered an increased number of patients with PMR features and without elevation of IgG4 disease to have simultaneous GCA.

Polymyalgia Rheumatica - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polymyalgia Rheumatica pipeline landscape is provided which includes the disease overview and Polymyalgia Rheumatica treatment guidelines. The assessment part of the report embraces, in depth Polymyalgia Rheumatica commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polymyalgia Rheumatica collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Polymyalgia Rheumatica. The therapies under development are focused on novel approaches to treat/improve Polymyalgia Rheumatica.

Polymyalgia Rheumatica Emerging Drugs

SPI-62: Sparrow Pharmaceuticals
SPI-62 is our proprietary, oral small molecule, new chemical entity, HSD-1 inhibitor, designed to reduce intracellular cortisol levels and mitigate its numerous adverse effects. We are currently developing SPI-62 for conditions directly caused by an overproduction of cortisol in the body..

Polymyalgia Rheumatica: Therapeutic Assessment

This segment of the report provides insights about the Polymyalgia Rheumatica drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Polymyalgia Rheumatica

There are approx. 5+ key companies which are developing the therapies Polymyalgia Rheumatica. The companies which have their Polymyalgia Rheumatica drug candidates in the most advanced stage, i.e Phase III include Bristol-Myers Squibb

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Polymyalgia Rheumatica pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polymyalgia Rheumatica: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polymyalgia Rheumatica therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polymyalgia Rheumatica drugs.

Polymyalgia Rheumatica Report Insights

• Polymyalgia Rheumatica Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Polymyalgia Rheumatica Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Polymyalgia Rheumatica drugs?
• How many Polymyalgia Rheumatica drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polymyalgia Rheumatica?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Polymyalgia Rheumatica therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Polymyalgia Rheumatica and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bristol-Myers Squibb
• Eli Lilly and Company
• Chugai Pharmaceutical
• Sparrow Pharmaceuticals

Key Products

• Abatacept
• Baricitinib
• Tocilizumab
• SPI 62
• SPI 47

This product will be delivered within 2 business days.